Brief: Vertex Pharmaceuticals Inc - FDA Expands Indication For Trikafta In Cf Patients Ages 2 And Older
01/04/2026 13:35
Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES US FDA APPROVAL FOR LABEL EXTENSIONS OF ALYFTREK® AND TRIKAFTA®, EXPANDING AVAILABILITY OF THESE MEDICINES TO ~95% OF ALL PEOPLE WITH CF IN THE UNITED STATES VERTEX PHARMACEUTICALS INC - FDA EXPANDS INDICATION FOR TRIKAFTA IN CF PATIENTS AGES 2 AND OLDER Source text: ID:nBw1FdLsya Further company coverage: VRTX.O
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria